As cancer diagnostics firm Neoprobe (NYSE Amex: NEOP) marches toward FDA approval of its “game-changing” radiopharmaceutical Lymphoseek and its share price continues to climb, many of the company’s ...
Neoprobe‘s (NYSE Amex:NEOP) largest shareholder said it’s considering launching a proxy fight aimed at installing three new directors on the cancer diagnostics company’s board. Platinum-Montaur Life ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback